Application | Comment | Organism |
---|---|---|
medicine | natural polymorphism C609T may affect amrubicin-related pharmacokinetics and clinical outcomes in lung cancer treatment. At a dose of 40 mg/m2, the T/T genotype exhibits a tendency toward a relationship with decreased concentrations of amrubicinol on days 2 and 4 of treatment. The genotype also shows a significant decrease of hematological toxicities | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
C609T | natural polymorphism which may affect amrubicin-related pharmacokinetics and clinical outcomes in lung cancer treatment. At a dose of 40 mg/m2, the T/T genotype exhibits a tendency toward a relationship with decreased concentrations of amrubicinol on days 2 and 4 of treatment. The genotype also shows a significant decrease of hematological toxicities | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P15559 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
lung | lung cancer tissue | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
NAD(P)H + H+ + amrubicin | - |
Homo sapiens | NAD(P)+ + ? | - |
? | |
NAD(P)H + H+ + amrubicinol | - |
Homo sapiens | NAD(P)+ + ? | - |
? |